

SUPPLEMENTAL MATERIAL

Table 1. Patients' characteristics and outcome

Patient#	Age	Gender	Medications	Structural heart disease	Duration of AF (years)	AF Type	# previous ablations	DF gradient in EGMs	DF gradient in BSPM	DF guided ablation	SR conversion during ablation
1	47	M	Flecainide, Bisoprolol	No	3	Parox	3	Yes	Yes	No	Yes
2	54	M	Flecainide	No	7	Parox	1	Yes	Yes	No	Yes
3	64	M	Flecainide, Atenolol	No	4	Parox	1	Yes	Yes	DF abl. after CPVI	Yes
4	49	M	Atenolol	No	3	Parox	3	Yes	Yes	Yes	No
5	51	M	Flecainide, Atenolol	No	2	Parox	1	Yes	Yes	No	No
6	60	M	Digoxine	No	3	Persist	0	Yes	Yes	No	No
7	61	M	Propafenone	No	17	Parox	2	Yes	Yes	DF abl. after CPVI	No
8	47	M	Carvediol, Digoxine	TCM	3	Persist	1	Yes	No	Yes (followed by CPVI)	No
9	59	M	Atenolol	No	5	Persist	0	No	No	No	No
10	65	M	Atenolol	No	5	Persist	1	Yes	No	No	No
11	68	F	Atenolol	No	7	Parox	0	Yes	Yes	No	No
12	67	M	Flecainide, Bisoprolol	No	10	Parox	1	No	No	DF abl. after CPVI	No
13	47	M	Bisoprolol	Ischemic	1	Parox	0	Yes	Yes	No	Yes
14	49	M	Bisoprolol	No	2	Parox	0	Yes	No	No	Yes

M: male; F: female; TCM: tachycardiomyopathy; Parox: paroxysmal AF; Persist: persistent AF; SR: sinus rhythm